Role of HER2 in wound-induced breast carcinoma proliferation

Lancet

Volumn 362, Issue 9383, 2003, Pages 527-533

  Tagliabue, Elda ^a   Agresti, Roberto ^a   Carcangiu, Maria Luisa ^a   Ghirelli, Cristina ^a   Morelli, Daniele ^a   Campiglio, Manuela ^a   Martel, Maritza ^a   Giovanazzi, Riccardo ^a   Greco, Marco ^a   Balsari, Andrea ^a   Ménard, Sylvie ^a,b  

^a UNIVERSITY OF MILAN   (Italy)

^b NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CREATINE KINASE; GROWTH FACTOR; HER 2 ANTIBODY; HUMAN EPIDERMAL RECEPTOR 2; ONCOPROTEIN; TRASTUZUMAB; UNCLASSIFIED DRUG;

ARTICLE; BODY REGIONS; BREAST CARCINOMA; CANCER SURGERY; CANCER TISSUE; CELL DAMAGE; CLINICAL ARTICLE; COLORIMETRY; CONTROLLED STUDY; CORRELATION ANALYSIS; DOWN REGULATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOCHEMISTRY; ISOTOPE LABELING; METASTASIS; ONCOGENE NEU; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SERUM; STATISTICAL SIGNIFICANCE; SURGICAL WOUND; TISSUE SECTION; WOUND DRAINAGE;

EID: 0041572902     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(03)14112-8     Document Type: Article

References (32)

1. Demicheli R., Terenziani M., Valagussa P., Moliterni A., Zambetti M., Bonadonna G. Local recurrences following mastectomy: support for the concept of tumor dormancy. J Natl Cancer Inst. 86:1994;45-48.
2. Fisher B., Anderson S., Bryant J., et al. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med. 347:2002;1233-1241.
3. Ménard S., Balsari A., Casalini P., et al. HER2-positive breast carcinomas as a particular subset with peculiar clinical behaviors. Clin Cancer Res. 8:2002;520-525.
4. Baker D.G., Masterson T.M., Pace R., Constable W.C., Wanebo H. The influence of the surgical wound on local tumor recurrence. Surgery. 106:1989;525-532.
5. Schuh A.C., Keating S.J., Monteclaro F.S., Vogt P.K., Breitman M.L. Obligatory wounding requirement for tumorigenesis in v-jun transgenic mice. Nature. 346:1990;756-760.
6. Morgenstern L., Yamakawa T., Seltzer D. Carcinoma of the gastric stump. Am J Surg. 125:1973;29-38.
7. Watson D.I. Abdominal wall metastasis after laparoscopic gastroenterostomy. Med J Aust. 163:1995;106-107.
8. Hofer S.O., Shrayer D., Reichner J.S., Hoekstra H.J., Wanebo H.J. Wound-induced tumor progression: a probable role in recurrence after tumor resection. Arch Surg. 133:1998;383-389.
9. Rowley D.R. What might a stromal response mean to prostate cancer progression? Cancer Metastasis Rev. 17:1998;411-419.
10. Iozzo R.V. Tumor stroma as a regulator of neoplastic behavior. Agonistic and antagonistic elements embedded in the same connective tissue. Lab Invest. 73:1995;157-160.
11. Ronnov-Jessen L., Petersen O.W., Bissell M.J. Cellular changes involved in conversion of normal to malignant breast: importance of the stromal reaction. Physiol Rev. 76:1996;69-125.
12. Hansbrough J.F., Bender E.M., Zapata-Sirvent R., Anderson J. Altered helper and suppressor lymphocyte populations in surgical patients. A measure of postoperative immunosuppression. Am J Surg. 148:1984;303-307.
13. Cole W.H. The increase in immunosuppression and its role in the development of malignant lesions. J Surg Oncol. 30:1985;139-144.
14. Decker D., Schondorf M., Bidlingmaier F., Hirner A., von Ruecker A.A. Surgical stress induces a shift in the type-1/type-2 T-helper cell balance, suggesting down-regulation of cell-mediated and up-regulation of antibody-mediated immunity commensurate to the trauma. Surgery. 119:1996;316-325.
15. Fisher B., Gunduz N., Coyle J., Rudock C., Saffer E. Presence of a growth-stimulating factor in serum following primary tumor removal in mice. Cancer Res. 49:1989;1996-2001.
16. Fisher B., Wickerham D.L., Deutsch M., Anderson S., Redmond C., Fisher E.R. Breast tumor recurrence following lumpectomy with and without breast irradiation: an overview of recent NSABP findings. Semin Surg Oncol. 8:1992;153-160.
17. Hsu S.M., Raine L., Fanger H. The use of antiavidin antibody and avidin-biotin-peroxidase complex in immunoperoxidase technics. Am J Clin Pathol. 75:1981;816-821.
18. Carter P., Presta L., Gorman C.M., et al. Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc Natl Acad Sci USA. 89:1992;4285-4289.
19. Pizao P.E., Lyaruu D.M., Peters G.J., et al. Growth, morphology and chemosensitivity studies on postconfluent cells cultured in 'V'-bottomed microtiter plates. Br J Cancer. 66:1992;660-705.
20. Marikovsky M., Breuing K., Yu Liu P., et al. Appearance of heparin-binding EGF-like growth factor in wound fluid as a response to injury. Proc Natl Acad Sci USA. 90:1993;3889-3893.
21. Klauke R., Schmidt E., Lorentz K. Recommendations for carrying out standard ECCLS procedures (1988) for the catalytic concentrations of creatine kinase, aspartate aminotransferase, alanine aminotransferase and gamma-glutamyltransferase at 37 degrees C. Standardization Committee of the German Society for Clinical Chemistry, Enzyme Working Group of the German Society for Clinical Chemistry. Eur J Clin Chem Clin Biochem. 31:1993;901-909.
22. Tagliabue E., Castiglioni F., Ghirelli C., et al. NGF co-operates with p185HER2 in activating growth of human breast carcinoma cells. J Biol Chem. 275:2000;5388-5394.
23. Blotnick S., Peoples G.E., Freeman M.R., Eberlein T.J., Klagsbrun M. T lymphocytes synthesize and export heparin-binding epidermal growth factor-like growth factor and basic fibroblast growth factor, mitogens for vascular cells and fibroblasts: differential production and release by CD4+ and CD8+ T cells. Proc Natl Acad Sci USA. 91:1994;2890-2894.
24. Higashiyama S., Abraham J.A., Miller J., Fiddes J.C., Klagsbrun M. A heparin-binding growth factor secreted by macrophage-like cells that is related to EGF. Science. 251:1991;936-939.
25. Todaro G.J., Fryling C., De Larco J.E. Transforming growth factors produced by certain human tumor cells: polypeptides that interact with epidermal growth factor receptors. Proc Natl Acad Sci USA. 77:1980;5258-5262.
26. Haffty B.G. Molecular and genetic markers in the local-regional management of breast cancer. Semin Radiat Oncol. 12:2002;329-340.
27. Ménard S., Tagliabue E., Campiglio M., Pupa S.M. Role of HER2 gene overexpression in breast carcinoma. J Cell Physiol. 182:2000;150-162.
28. Mizutani J., Hiraoka T., Yamashita R., Miyauchi Y. Promotion of hepatic metastases by liver resection in the rat. Br J Cancer. 65:1992;794-797.
29. Schindel D.T., Grosfeld J.L. Hepatic resection enhances growth of residual intrahepatic and subcutaneous hepatoma, which is inhibited by octreotide. J Pediatr Surg. 32:1997;995-997.
30. Graus-Porter D., Beerli R.R., Daly J.M., Hynes N.E. ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a medicitor of lateral signaling. EMBO J. 16:1997;1647-1655.
31. Sieweke M.H., Bissell M.J. The tumor-promoting effect of wounding: a possible role for TGF-beta-induced stromal alterations. Crit Rev Oncog. 5:1994;297-311.
32. Veronesi U., Saccozzi R., Del Vecchio M., et al. Comparing radical mastectomy with quadrantectomy, axillary dissection, and radiotherapy in patients with small cancers of the breast. N Engl J Med. 305:1981;6-11.